Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Adenocarcinoma 2Pancreatic Ductal Adenocarcinoma 1Neoplasms 1Carcinoma, Pancreatic Ductal 1

Interventions

Gemcitabine 5MK-4721 2130-nm albumin-bound paclitaxel 2selinexor 1relacorilant 1ponatinib 1neratinib 1folfirinox 1contrast agent BR1 1cobimetinib 1ceritinib 1brigatinib 1abemaciclib 1S 1 (combination) 1Radiotherapy 1Radiosurgery 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Irinotecan 1Floxuridine 1Etoposide 1Enoxaparin 1Drug Therapy 1Doxorubicin 1Dexamethasone 1Colchicine 1Capecitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Pancreatic Ductal × PEGPH20 × Clear all
NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 2 Completed
279 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡